Holen Sie sich die Stockscreener-App
81.88
4.45%
3.49
Handel nachbörslich:
80.20
-1.68
-2.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$78.39
Offen:
$78.27
24-Stunden-Volumen:
1.90M
Relative Volume:
0.83
Marktkapitalisierung:
$12.42B
Einnahmen:
$4.39B
Nettoeinkommen (Verlust:
$-1.58B
KGV:
-8.2209
EPS:
-9.96
Netto-Cashflow:
$546.00M
1W Leistung:
-1.15%
1M Leistung:
-7.73%
6M Leistung:
-41.10%
1J Leistung:
-36.29%
1-Tages-Spanne:
$77.99
$82.76
1-Wochen-Bereich:
$77.54
$83.09
52-Wochen-Spanne:
$77.54
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
81.88 | 12.42B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
How Illumina employees step up, reach out, and give back - Illumina
Characterizing alveolar dysregulation in pulmonary fibrosis using Illumina Spatial Technology - Illumina
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today - Benzinga
Argus cuts Illumina target, sees buying opportunity - Yahoo Finance
Illumina careers: Expanding access to NGS in emerging markets - Illumina
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Nasdaq
Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Artisan Partners Limited Partnership - MarketBeat
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders - NBC Connecticut
Illumina stock hits 52-week low at $80.18 amid market challenges By Investing.com - Investing.com South Africa
Illumina stock hits 52-week low at $80.18 amid market challenges - Investing.com India
New in the lab: Test driving the MiSeq i100 Plus - Illumina
Analyst recommendations: Illumina, Boeing, Next, Walmart, Applovin.... - MarketScreener
AI In Genomics Market to Reach $9.8 Billion, Globally, by 2031 - openPR
NGS Sample Preparation Market Techniques Reshaping Genomic - openPR
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock By Investing.com - Investing.com South Africa
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock - Investing.com
Illumina Adds Activist to Board, Names Former FDA Chief as Chair - MSN
May 9th Options Now Available For Illumina (ILMN) - Nasdaq
Is Illumina Undervalued After An 83% Drop In Its Stock Price? (NASDAQ:ILMN) - Seeking Alpha
Illumina is Now Oversold (ILMN) - Nasdaq
Canaccord maintains Illumina stock hold with $115 target By Investing.com - Investing.com UK
Activist investor Keith Meister to join Illumina's board - Reuters
Activist Investors Seize More Control of Illumina Amid Weakness - Markets Insider
Canaccord holds Illumina stock with $115 target amid board changes By Investing.com - Investing.com UK
Cintas, UPS, Illumina: Market Minute - Yahoo Finance
Illumina rises after board revamp - MSN
Illumina stock rises after board revamp (ILMN:NASDAQ) - Seeking Alpha
Activist Investor Meister to Join Illumina’s Board - WSJ
Activist investor Keith Meister to join Illumina’s board, WSJ reports - 1470 & 100.3 WMBD
Illumina Names Scott Gottlied as Non-Executive Board Chair; Corvex's Keith Meister Joins Board - MarketScreener
Illumina Board Of Directors Elects Dr. Scott Gottlieb Chair, Keith Meister To Join Board Of Directors - MarketScreener
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors - PR Newswire
Activist investor Keith Meister to join Illumina's board, WSJ reports - MSN
Illumina shares rise on WSJ report activist investor Meister will join board By Investing.com - Investing.com UK
Activist investor Meister to join Illumina's board, WSJ reports - MarketScreener
Activist Investor Keith Meister Will Join The Board Of Directors Of Illumina- WSJ - MarketScreener
Single Cell Genome Sequencing Market Detailed In New Research - openPR
High End Cellomics Market Set to Witness Significant Growth - openPR
Scaling the genomics lab for the data deluge - Illumina
Illumina CIO Carissa Rollins to retire in April By Investing.com - Investing.com Australia
Illumina CIO Carissa Rollins to retire in April - Investing.com
Interrogating challenging genomic regions provides new answers for patients - Illumina
Unlocking a world of complete biological understanding - Illumina
Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now? - Insider Monkey
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain? - Yahoo Finance
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
1.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):